Feline Cryptococcosis: Staging and Treatment Decisions

Bottom line

Feline cryptococcosis requires confirmation and assessment of disease distribution before a treatment plan is chosen. Antigen testing and lesion sampling address diagnosis; imaging helps define extension but does not confirm infection by itself. [1] Separate control of the presenting nasal lesion, possible ocular or CNS involvement, drug tolerance, and longer-term relapse surveillance.

Confirm infection before treating a nasal appearance

The ABCD guideline identifies blood antigen detection as a useful minimally invasive test. False negatives can occur; persistent suspicion despite a negative result warrants suitable tissue samples for cytology, histology and culture. Antibody detection does not distinguish subclinical infection from disease. [1]

Record the assay, specimen type, reported result and units, previous antifungal exposure, and which lesion was sampled. If results disagree, explain which finding supports infection and what remains unresolved rather than converting every nasal mass into presumed cryptococcosis.

The feline epistaxis workup covers the broader local-versus-systemic investigation before a fungal diagnosis is supported. A disease-specific pathway should refine that evaluation, not erase a competing bleeding disorder or another nasal lesion.

Stage the disease without assuming nasal signs define its extent

The Australian CNS cohort included both cats and dogs and combined retrospective and prospective investigation. Extraneurologic signs were common, and the authors caution that absence of neurologic signs does not exclude CNS involvement. [2]

Perform and document a neurologic and ocular assessment alongside evaluation of the presenting lesion. Discuss whether imaging or additional sampling would change treatment, prognosis counseling or the care setting. Keep suspected extension distinct from confirmed extension in the referral.

Uveitis also has other infectious causes. The ocular FIP reference addresses a different disease-specific pathway when that diagnosis is independently supported. An inflamed eye alone should not select either antiviral or antifungal treatment.

Make CSF sampling a specific diagnostic decision

The CNS cohort associated CSF collection with shorter survival in cats. [2] That association is not proof that collection itself caused the outcome; patient selection and disease severity require consideration.

The ABCD guideline advises reserving CSF collection for compatible CNS disease that cannot be confirmed using other suitable samples because herniation risk is a concern. [1] State the question the procedure must answer and whether serum testing or an accessible lesion can answer it more safely. Review imaging and procedural risk with the neurologist rather than treating a CSF sample as an automatic staging requirement.

Do not apply the cohort's dog-specific associations to cats. Its mixed-species population and treatment selection also prevent interpreting the reported treated survival experience as a guaranteed feline prognosis. [2]

Select antifungal treatment by site and patient constraints

The antifungal review favors fluconazole for rhinitis and localized cutaneous disease. CNS, ocular or disseminated disease generally calls for amphotericin B combined with flucytosine, or fluconazole when flucytosine is unavailable. [3]

Review renal function, hepatic findings, concurrent medication, formulation availability, and the ability to deliver prolonged treatment before selecting a regimen. Amphotericin B nephrotoxicity and azole-associated hepatic adverse effects require monitoring matched to the product and patient. [3] Where use is extra-label, document that status and verify the applicable prescribing requirements. No universal dose or cumulative target is supplied here.

Define what will trigger reassessment: clinical deterioration, intolerance, failure of the presenting lesion to improve, or an antigen trajectory inconsistent with the rest of the case. A change in medication should have a recorded reason and follow-up plan rather than being described only as “azole failure.”

Use titers with clinical response, not as an isolated cure label

The long-term retrospective treatment cohort found that some animals recrudesced despite reduction of serum antigen titers to zero. It also compared different protocols in patients with different disease severity. [4] Neither an undetectable result nor an apparently favorable group outcome eliminates the need for clinical follow-up.

The antifungal review describes selected refractory cases in which a persistent titer plateau may be interpreted alongside clinical remission after other treatment approaches. [3] This is not a general instruction to stop treatment at any low positive titer. Reconcile the assay trend, lesion response, adherence, treatment tolerance, and suspected disease distribution with the treating specialist.

Explain the monitoring plan before stopping or changing therapy. Specify who reviews results and what clinical or laboratory change would reopen the treatment decision. Keep a record of the pretreatment assay and disease sites so later recurrence can be compared with the original presentation.

Consider lesion reduction as an adjunct

Selected large granulomas may be considered for surgical excision or debridement, but the review finds no evidence that this shortens treatment or is superior to medical therapy alone. [3] Plan around obstruction, accessibility, tissue risk and the systemic treatment plan; removal of a visible mass is not evidence that disseminated infection is resolved.

Frequently Asked Questions

Does a negative serum antigen result exclude cryptococcosis?

No. The ABCD guideline recommends lesion sampling for cytology, histology and culture when suspicion persists despite a negative antigen result. [1]

Can imaging alone confirm the diagnosis?

No. Imaging maps lesions, while antigen testing and organism-directed sampling address confirmation. [1]

Does absence of neurologic signs exclude CNS involvement?

No. The Australian CNS cohort specifically cautions that it does not. [2]

Does the CSF–survival association prove that sampling caused death?

No. The cohort identified an association in cats, not a randomized causal effect of the procedure. [2]

Are localized nasal and severe CNS cases treated identically?

No. The antifungal review distinguishes fluconazole for localized disease from amphotericin-containing combination treatment for CNS or severe disease. [3]

Does a negative antigen titer guarantee no relapse?

No. Recrudescence occurred in the long-term cohort even after serum antigen titers had fallen to zero. [4]

Does debulking have a proven advantage over antifungal therapy alone?

No. The antifungal review describes selected use but no evidence of shorter treatment or superiority over medical therapy alone. [3]